Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.39B | $9.05B | $9.82B | $10.7B | $9.91B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Revenue growth | — | 7.9% | 8.6% | 9.3% | -7.7% | 19.9% | 6.7% | 12.3% | 17.6% | 19.9% |
| Gross profit | $5.96B | $6.46B | $7.01B | $7.62B | $6.45B | $8.18B | $8.73B | $9.90B | $11.5B | $13.9B |
| Gross margin | 71.1% | 71.3% | 71.4% | 71.0% | 65.0% | 68.8% | 68.8% | 69.5% | 68.6% | 69.0% |
| Operating income | $447M | $1.28B | $1.51B | $1.52B | -$80.0M | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B |
| Operating margin | 5.3% | 14.2% | 15.3% | 14.1% | -0.8% | 10.1% | 13.0% | 16.5% | 15.5% | 18.0% |
| Net income | $347M | $104M | $1.67B | $4.70B | -$82.0M | $1.04B | $698M | $1.59B | $1.85B | $2.89B |
| Net margin | 4.1% | 1.1% | 17.0% | 43.8% | -0.8% | 8.8% | 5.5% | 11.2% | 11.0% | 14.4% |
| EPS (diluted) | $0.25 | $0.08 | $1.19 | $3.33 | -$0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.18B | $1.43B | $310M | $1.84B | $1.51B | $1.87B | $1.53B | $2.50B | $3.44B | $4.53B |
| Capital expenditures | $376M | $319M | $316M | $461M | $376M | $554M | $588M | $711M | $790M | $876M |
| Free cash flow | $806M | $1.11B | -$6.00M | $1.38B | $1.13B | $1.32B | $938M | $1.79B | $2.65B | $3.66B |
| Share buybacks | $0.00 | — | $0.00 | $0.00 | $535M | $0.00 | $0.00 | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | $28.0M | $55.0M | $55.0M | $28.0M | $0.00 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $196M | $188M | $146M | $217M | $1.73B | $1.93B | $928M | $865M | $414M | $1.97B |
| Total assets | $18.1B | $19.0B | $21.0B | $30.6B | $30.8B | $32.2B | $32.5B | $35.1B | $39.4B | $43.7B |
| Long-term debt | $5.42B | $3.81B | — | — | — | — | — | — | — | — |
| Shareholders' equity | $6.73B | $7.01B | $8.73B | $13.9B | $15.3B | $16.6B | $17.6B | $19.3B | $21.8B | $24.2B |
| Retained earnings | -$8.58B | -$8.39B | -$6.95B | -$2.25B | -$2.38B | -$1.39B | -$750M | $819M | $2.67B | $5.57B |
| Shares (wtd avg diluted) | 1.38B | 1.39B | 1.40B | 1.41B | 1.42B | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B |
Every figure is extracted from BOSTON SCIENTIFIC CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.